WHO Priority Pathogens List paper is published; Industry action report to be released

Dear All:

First, the methods behind the WHO Priority Pathogens List (PPL, released on 25 Feb 2017) have now been published by Tacconelli et al. in Lancet Infectious Diseases along with an editorial by Tillottson. As further context while you review these excellent papers, you might also find it helpful to have to hand this slide deck comparing the WHO PPL, the 2013 CDC threat list, and the 2008-9 ESKAPE pathogen list. (11 Feb 2020 addendum: I have updated that deck to also show the CDC 2019 threat list. Get the new deck here, go here for a newsletter about CDC’s update, and go here for a discussion of the problem of setting antibiotic R&D priorities.)

You should read the papers yourself, but the quick summary is that the authors used multicriteria decision analysis across 10 axes (mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline) to prioritize the pathogens. Very importantly, they obtained input from 70 experts spanning all 6 WHO regions, thus ensuring a broad view on global needs.

Second, there has been a lot of action underway to address the gaps identified by the WHO PPL and the related WHO pipeline review from this past summer. I am seeing significant amounts of company-level activity and one measure of this is that CARB-X now lists 22 projects in its portfolio page. As an additional perspective on recent actions at the Industry level, I’ve learned that the AMR Industry Alliance will release its first Global Progress report on 18 Jan 2018 in Geneva. You can register to attend that meeting via this link. This is all very exciting to see!

In closing, all best wishes for the holidays and thank you for being one of the just over 1,000 subscribers to this newsletter! I’ve enjoyed writing these occasional updates and I’ve also appreciated all the helpful comments and tips that I’ve received. 

Ho, ho, ho! –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:


AI-based drug discovery: Chemical vs. drugs (Part 4)

Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the original report has a new paper about identification of a narrow-spectrum compound with activity vs. Acinetobacter baumannii. Here are the links you’ll

WHO-UNEP-FAO-OIE Youth Engagement Working Group on AMR: Apply now!

“Education is the most powerful weapon we can use to change the world…” — Nelson Mandela Dear All, Regular readers will know my interest in developing the ecosystem of people who will work to address AMR over time (e.g., this interview with the founder of the Future Leaders Against AMR, my strong support for the

Reports calling for Pull: US GAO, Global AMR R&D Hub

Dear All, Two important reports for your awareness this afternoon. First, the Global AMR R&D hub have responded to a request from the G7 Finance and Health Ministers to provide an update to their 2022 progress report in advance of upcoming G7 meetings. As background, recall that the Finance Ministers in 2021 (during the UK G7

High Watermark for Pull Incentives (and more): Reflections on an amazing week!

Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …

Scroll to Top